Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: A phase 2 trial

By Abou-Jawde Rony   Reed Janice   Kelly Megan   Walker Esteban   Andresen Steven   Baz Rachid   Karam Mary   Hussein Mohamad  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 263-272

Humana Press, Inc

Access to resources Recommend Favorite

Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome

By Chim C.  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 181-182

Springer Publishing Company

Access to resources Recommend Favorite

The evolution and impact of therapy in multiple myeloma

By Laubach Jacob   Richardson Paul   Anderson Kenneth  

Medical Oncology, Vol. 27, Iss. 1, 2010-06 ,pp. : 1-6

Humana Press, Inc

Access to resources Recommend Favorite

A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma

By Held Lauren A.   Rizzieri David   Long Gwynn D.   Gockerman Jon P.   Diehl Louis F.   Castro Carlos M. de   Moore Joseph O.   Horwitz Mitchell E.   Chao Nelson J.   Gasparetto Cristina  

Cancer Investigation, Vol. 31, Iss. 3, 2013-03 ,pp. : 172-176

Informa Healthcare

Access to resources Recommend Favorite

Phase II Trial of rhIL-6 (Interleukin-6) Prior to and Concurrently with VAD (Vincristine, Doxorubicin and Dexamethasone) Chemotherapy for Patients with Multiple Myeloma

By Young R.I.   Ranson M.   Chang J.   Lord B.   Testa N.   Scarffe J.H.  

European Journal of Cancer, Vol. 33, Iss. 2, 1997-02 ,pp. : 307-311

Elsevier

Access to resources Recommend Favorite